BR9909256A - 2- trans- (4-aminociclohexil)amino]purinas 6,9-di-substituìdas - Google Patents

2- trans- (4-aminociclohexil)amino]purinas 6,9-di-substituìdas

Info

Publication number
BR9909256A
BR9909256A BR9909256-5A BR9909256A BR9909256A BR 9909256 A BR9909256 A BR 9909256A BR 9909256 A BR9909256 A BR 9909256A BR 9909256 A BR9909256 A BR 9909256A
Authority
BR
Brazil
Prior art keywords
formula
inhibiting
trans
amino
admixture
Prior art date
Application number
BR9909256-5A
Other languages
English (en)
Inventor
Jennifer A Dumont
Alan J Bitonti
David R Borcherding
Norton P Peet
H Randall Munson
Patrick W K Shum
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BR9909256A publication Critical patent/BR9909256A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"2-[TRANS-(4-AMINOCICLOHEXIL)AMINO]PURINAS 6,9-DI-SUBSTITUìDAS"<D>. Compostos da fórmula (I), em que R é selecionado do grupo consistindo em R2, R2NH- ou R3R4N-R5- e R1 é selecionado do grupo consistindo em ciclopentila, ciclopentenila e isopropila e os sais, isómeros ópticos e hidratos farmaceuticamente aceitáveis dos mesmos. A invenção proporciona um método de inibição da progressão do ciclocelular, um método de inibição das cinases ciclinadependentes, particularmente cdk-2, um método de prevenção da apoptose em células neuronais e um método de inibição do desenvolvimento de neoplasmas, uma composição compreendendo uma quantidade analisável de um composto da fórmula (I) em mistura ou, de outro modo, em associação com um veículo inerte e uma composição farmacêutica compreendendo uma quantidade inibitória eficaz de um composto da fórmula (I) em mistura ou, de outro modo, em associação com um ou mais veículos ou excipientes farmaceuticamente aceitáveis.
BR9909256-5A 1998-02-26 1999-02-18 2- trans- (4-aminociclohexil)amino]purinas 6,9-di-substituìdas BR9909256A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3097598A 1998-02-26 1998-02-26
US13510998P 1998-02-26 1998-02-26
US09/247,053 US6479487B1 (en) 1998-02-26 1999-02-09 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
PCT/US1999/003450 WO1999043675A1 (en) 1998-02-26 1999-02-18 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines

Publications (1)

Publication Number Publication Date
BR9909256A true BR9909256A (pt) 2000-11-28

Family

ID=27363758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909256-5A BR9909256A (pt) 1998-02-26 1999-02-18 2- trans- (4-aminociclohexil)amino]purinas 6,9-di-substituìdas

Country Status (17)

Country Link
US (1) US6479487B1 (pt)
EP (1) EP1056744B1 (pt)
JP (1) JP2002504552A (pt)
CN (1) CN1143858C (pt)
AP (1) AP1054A (pt)
AU (1) AU747151B2 (pt)
BR (1) BR9909256A (pt)
CA (1) CA2320474C (pt)
EE (1) EE04815B1 (pt)
HU (1) HUP0100889A3 (pt)
IL (1) IL138043A0 (pt)
NO (1) NO328509B1 (pt)
PL (1) PL194174B1 (pt)
SK (1) SK12902000A3 (pt)
TR (1) TR200002463T2 (pt)
WO (1) WO1999043675A1 (pt)
ZA (1) ZA991551B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
DE60118521T2 (de) * 2000-01-07 2006-10-12 Universitaire Instelling Antwerpen Purin derivate, ihre herstellung und verwendung
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
MXPA03001189A (es) 2000-08-09 2004-05-14 Agouron Pharma Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas.
EP1309563B1 (en) 2000-08-18 2005-05-11 Agouron Pharmaceuticals, Inc. Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
GB0117075D0 (en) * 2000-10-31 2001-09-05 Aventis Pharm Prod Inc Acyl and sulfonyl derivatives of 6, 9-distributed 2-(trans-1, 4-diaminocyclohexyl)-purines and their use as antiproliferative agents
MXPA03003774A (es) * 2000-10-31 2003-07-28 Aventis Pharm Prod Inc Derivados de acilo y sulfonilo de 2-(trans-1, 4-diaminociclohexil)-purinas 6,9-disubstituidas y sus uso como agentes antiproliferativos.
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
EP1569647B1 (en) * 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
KR100677396B1 (ko) * 2004-11-20 2007-02-02 엘지전자 주식회사 음성인식장치의 음성구간 검출방법
PL2448938T3 (pl) 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CN102295594B (zh) * 2011-07-12 2016-01-20 上海医药工业研究院 4-n-取代-1-(3-甲氧基丙基)-4-哌啶胺类化合物及制备和应用
CN102898356B (zh) * 2011-07-29 2015-08-26 上海医药工业研究院 1-(3-甲氧基丙基)-4-哌啶胺及其盐的制备方法
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
CN103193699B (zh) * 2013-04-18 2015-04-15 安徽赛诺医药化工有限公司 一种制备普卡必利中间体的新方法
CN103508939A (zh) * 2013-06-30 2014-01-15 北京万全德众医药生物技术有限公司 一种制备普卡必利中间体1-（3-甲氧基丙基）-4-哌啶胺的方法
CN103848777B (zh) * 2014-03-18 2016-04-13 悦康药业集团有限公司 一种n-(3-甲氧基丙基)-4-氨基哌啶的合成方法
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
AU2016222556B2 (en) 2015-02-27 2020-08-27 Incyte Holdings Corporation Salts of Pl3K inhibitor and processes for their preparation
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
TWI703150B (zh) * 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
SI3429591T1 (sl) 2016-03-16 2023-07-31 Kura Oncology, Inc. Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
WO2017161002A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
CZ308029B6 (cs) * 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液***恶性肿瘤和尤因肉瘤的方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
CN115677567A (zh) * 2022-11-15 2023-02-03 大唐环境产业集团股份有限公司 一种4-氨基-1-哌啶丙醇的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4232155A (en) 1979-09-13 1980-11-04 Bristol-Myers Company Purine compounds
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
AU658698B2 (en) 1991-12-06 1995-04-27 Aventis Pharmaceuticals Inc. Novel trans cyclopentanyl purine analogs useful as immunosuppressants
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5688665A (en) * 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
CN1066147C (zh) 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
EP1003746A1 (en) 1997-08-07 2000-05-31 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
CN1353713A (zh) 1999-02-01 2002-06-12 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB－α的嘌呤抑制剂
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation

Also Published As

Publication number Publication date
CN1292789A (zh) 2001-04-25
AU747151B2 (en) 2002-05-09
AP1054A (en) 2002-04-01
PL342604A1 (en) 2001-06-18
IL138043A0 (en) 2001-10-31
JP2002504552A (ja) 2002-02-12
CN1143858C (zh) 2004-03-31
EE04815B1 (et) 2007-04-16
NO328509B1 (no) 2010-03-08
NO20004280D0 (no) 2000-08-25
US6479487B1 (en) 2002-11-12
AP2000001922A0 (en) 2000-09-30
EE200000489A (et) 2002-04-15
TR200002463T2 (tr) 2000-12-21
PL194174B1 (pl) 2007-05-31
EP1056744A1 (en) 2000-12-06
NO20004280L (no) 2000-10-25
HUP0100889A3 (en) 2003-07-28
CA2320474C (en) 2005-05-10
EP1056744B1 (en) 2003-10-22
WO1999043675A1 (en) 1999-09-02
AU2770999A (en) 1999-09-15
ZA991551B (en) 1999-08-26
SK12902000A3 (sk) 2001-04-09
CA2320474A1 (en) 1999-09-02
HUP0100889A2 (hu) 2002-01-28

Similar Documents

Publication Publication Date Title
BR9909256A (pt) 2- trans- (4-aminociclohexil)amino]purinas 6,9-di-substituìdas
BR9908325A (pt) 6 9-dissubstituìdo 2-[trans-4(4-aminociclohexil)amino]purinas
BR0210384A (pt) Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
TR200001279T2 (tr) Poli (ADP-riboz) polimeraz (&#34;PARP&#34;) inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler.
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
BR9811774A (pt) Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp
AP1445A (en) Substituted 4-amino-thiazol-2-yl compounds as CDKs inhibitors.
PA8452201A1 (es) Derivados de 9-desoxo-9a-aza-9a -homoeritromicina a c-4&#34;sustituidos.
CY1112024T1 (el) Αναστολεις υποδοχεων adp αιμοπεταλιων
NO20052927L (no) 2,4,6-trisubstituerte pyrimidiner av fosfotidylinositol (PI) 3-kinaseinhibitorer og deres anvendelse ved behandling av kreft
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
TR199801530T2 (xx) VEGF �nhibit�rleri olarak kinazolin t�revleri.
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
BR9912866A (pt) Composto ou uma forma tautomérica, sal ousolvato farmaceuticamente aceitável do mesmo,composição farmacêutica, processo para otratamento ou a prevenção de uma doença, fatorde risco ou condição, mediada por hppar alfa e/ouhppar gama, e uso de um composto
BR9811099A (pt) Inibidores de urocinase
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2
BR0007589A (pt) Inibidores da proliferação de células
HUP0102255A2 (hu) VLA-4 inhibitor hatású oMePUPA-V, ezt tartalmazó gyógyszerkészítmény és alkalmazása
BR0113389A (pt) Compostos que inibem a atividade do fator xa
PT1336407E (pt) Composicao contendo um antagonista do receptor de angiotensina e um diuretico e sua utilizacao para o tratamento da hipertensao
DK0556329T3 (da) Substituerede piperaziner som midler til behandling af centralnervesystemet
DK0966277T3 (da) Anvendelse af R-NSAID&#39;er til forebyggelse af Alzheimer&#39;s sygdom

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 10,11, 13 E 25 DA LPI

B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070033918/RJ DE 19/03/2007.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: HMR PHARMA, INC. (US)

Free format text: TRANSFERIDO DE: AVENTIS PHARMACEUTICALS INC

B25A Requested transfer of rights approved

Owner name: AVENTIS HOLDINGS INC. (US)

Free format text: TRANSFERIDO DE: HMR PHARMA, INC.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA NO 020100040867/RJ DE 10/05/2010, POR AUSENCIA DE FUNDAMENTACAO LEGAL, EM VIRTUDE DO INDEFERIMENTO DO PEDIDO, PUBLICADO NA RPI 2083 DE 07/12/2010.

B25B Requested transfer of rights rejected

Owner name: AVENTIS HOLDINGS INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]